PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in Cranbury, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

CRANBURY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided corporate highlights.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Guillermina (Gigi) Lozano, Ph.D., to its Scientific Advisory Board (SAB).

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 2, 2020 at the Evercore ISI 3rd Annual HealthCONx Conference. The presentation will also be available on PMV's web site. Details on the presentation can be found below.

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced dosing of the first patient in its Phase 1/2 clinical trial evaluating PC14586, the company's investigational lead compound that targets the Y220C mutant of p53. The trial will enroll up to 130 patients with advanced solid tumors that have the specific p53 Y220C variant.

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the third quarter ended September 30, 2020, and provided corporate highlights.

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

Andreas Halvorsen (Trades, Portfolio) revealed he established a new position in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Sept. 25, according to GuruFocus' Real-Time Picks.

Andreas Halvorsen Jumps on PMV Pharmaceuticals

CRANBURY, N.J., Sept.  29, 2020  (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares of common stock, at a public offering price of $18.00 per share. The aggregate gross proceeds to PMV Pharma from the offering were approximately $243.5 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by PMV Pharma. PMV Pharma’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “PMVP.”

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering  and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Amesite Operating

Bentley Systems

Corsair Gaming

GoodRx Holdings

Greenwich Lifesciences

Graybug Vision

Laird Superfood

Prelude Therapeutics

Array Technologies

U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week

PMV Pharmaceuticals Inc.'s stock  debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m.

PMV Pharmaceutical's stock nearly doubles in its debut

PMV Pharmaceuticals Inc.'s 
        PMVP, 
          
       initial public offering priced at $18 a share, which was at the top of the expected range of $16 to $18 a share. The oncology company said late Thursday that it sold 11.765 million shares in the IPO, which was recently upsized from 7.35 million shares, to raise $211.8 million.

PMV Pharmaceuticals prices IPO at top end of expectations, raises $211.8 million

CRANBURY, N.J., Sept.  24, 2020  (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the pricing of its initial public offering of 11,765,000 shares of common stock at a public offering price of $18.00 per share. PMV Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on September 25, 2020 under the ticker symbol “PMVP.”

PMV Pharma Announces Pricing of Initial Public Offering

News for PMV Pharmaceuticals Stock (PMVP)